NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer
Rainer Fagerholm(358 (Finland)), Heli Nevanlinna(Helsinki University Hospital), Anne Kallioniemi(Tampere University Hospital), Päivi Heikkilä(University of Helsinki), Kristiina Aittomäki(Helsinki University Hospital), Matti Uusitupa, Johanna Tommiska(Helsinki University Hospital), Vesa Kataja(South Eastern Finland University of Applied Sciences), Carl Blomqvist(University of Helsinki), Outi Kilpivaara, Kirsi Syrjäkoski(Tampere University Hospital), Kirsimari Aaltonen(University of Helsinki), Karl von Smitten(Helsinki University Hospital), Jiřina Bártková(Cancer Institute (WIA)), Jiří Bártek(Science for Life Laboratory), Barbara Hofstetter(Danish Cancer Society), Kaija Holli(Tampere University Hospital), Radek Vrtěl(Danish Cancer Society), Veli‐Matti Kosma(University of Eastern Finland), Matti Eskelinen(Kuopio University Hospital)
Cited by 208
Related Papers
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k